Rattibha

@TumorBoardTues 56yo🧔🏽
Local #ProstateCancer
Sx: (-) margins & (-) nodes
PSA≤ 0.1 post-op
🗓️2yrs: PSA recurrence
ADT monotx, PSA <0.2
🗓️2yrs on ADT
PSA ⬆️ 16
🩻Restaging CT C/A/P & bone scan: 6 lesions
Asx
Dx: new mCRPC
Tumor CGP: PALB2 mutation
What next?

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi 2/19 #TumorBoardTuesday @MPishvaian @JohnEbbenMDPhD @shilpaonc #ProstateCancer @neerajaiims
What if…
68yo 👨🏽‍🦳 with mCSPC
On ADT monoRx for 3 years
🧪PSA ⬆️ 60
🩻Restaging scans: new bone mets
Tumor CGP: BRCA2 mutation
🤔 What would NOT be an appropriate next line of Rx?

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims 3/19 #TumorBoardTuesday
What if…
52yo 👨🏻‍🦱
synchronous high volume mCSPC
Triplet tx with ADT+ docetaxel + AAP
PSA: ⬇️0.2 ng/ml
👨🏻‍🦱break from abiraterone d/t HTN despite medical mgmt
🗓️1 year
👨🏻‍🦱Dx: mCRPC
Rising PSA
3 new asymptomatic 🦴 lesions
Tumor CGP: RAD51C mutation
🤨Next?

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @CParkMD

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @CParkMD 4/19 #TumorBoardTuesday @Uromigos
👨🏽‍🏫Mini Tweetorial 1👨🏽‍🏫
📌Genomic HRR alterations in metastatic #ProstateCancer
📍692 men
✅mCRPC germline DNA-repair gene mutations
📍82 men (11.8%) - most common:
BRCA2 44%
ATM 13%
CHEK2 12%
BRCA1 7%
📚@quimmateo nejm.org

nejm.org/doi/full/10.10…

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | NEJM

Original Article from The New England Journal of Medicine — Inherited DNA-Repair Gene Mutations in M...

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @CParkMD @Uromigos @quimmateo 5/19 #TumorBoardTuesday
👨🏽‍🏫Mini Tweetorial 2👨🏽‍🏫
📌Comprehensive Genomic Profiling of primary & metastatic prostate tumors
📍most frequently altered
TP53 (43.5%)
PTEN (32.2%)
TMPRSS2-ERG (31.2%)
AR (22.5%)
MYC (12.3%)
BRCA2 (9.8%)
RB1 (9.7%)
📚@EthanSokol ascopubs.org

ascopubs.org/doi/10.1200/PO…

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

PURPOSE Comprehensive genomic profiling (CGP) is increasingly used for routine clinical management o...

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @CParkMD @Uromigos @quimmateo 6/19 #TumorBoardTuesday
👨🏽‍🏫Mini Tweetorial 3👨🏽‍🏫
📌MoA of PARPi
🔹Recruited to single-strand DNA damage sites, activating base excision repair path
🔸Trigger HRR path, enabling cell survival
🔹Combo HRR gene mutations result in cell death
📚@RebeccaDSing ascopubs.org

ascopubs.org/doi/10.1200/JC…

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

The DNA damage response (DDR) pathway coordinates the identification, signaling, and repair of DNA d...

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira 7/19 #TumorBoardTuesday
👨🏽‍🏫Mini Tweetorial 4👨🏽‍🏫
📌3 approved PARPi + ARPI 1L combos
✨TALAPRO-2: Enzalutamide + talazoparib- HRR
📚@neerajaiims
✨PROpel: Olaparib + abiraterone- BRCA
📚@AarmstrongDuke
✨MAGNITUDE: Niraparib + abiraterone- BRCA
📚@AttardLab @EfstathiouEleni

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab 8/19 #TumorBoardTuesday #ASCO23 #GU23
👨🏽‍🏫Mini Tweetorial 5👨🏽‍🏫
✨TALAPRO-2
📍Cohort B included only HRR-mutated mCRPC
📍HRR gene alterations assessed: BRCA1/2, PALB2, ATM, ATR, CHEK2, FANCA, RAD51C, NBN,
MLH1, MRE11A, CDK12
📚@neerajaiims @AzadOncology pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/37285865/

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - PubMed

Pfizer.

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @AzadOncology 9/19 #TumorBoardTuesday #GU23 @maughanonc
👨🏽‍🏫Mini Tweetorial 6👨🏽‍🏫
✨TALAPRO-2 cohort B
📍399 HRR mutated 1L mCRPC
🤼 200 (Tala + Enza) vs 199 (PBO + Enza)
📈rPFS HR 0.46
📉OS data immature

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @AzadOncology @maughanonc 10/19 #TumorBoardTuesday #ProstateCancer
👨🏽‍🏫Mini Tweetorial 7👨🏽‍🏫
✨PROpel
📍796 1L mCRPC pts (HRRm & non-HRRm)
🤼398 (Abi + olaparib) vs 396 (Abi + PBO)
📈HRRm: rPFS HR 0.5 (in favor of abi + olaparib)
📈non-HRRm: rPFS HR 0.76 (in favor of abi + olaparib)
📚evidence.nejm.org

evidence.nejm.org/doi/full/10.10…

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Preclinical studies and results of a phase 2 trial of abiraterone and olaparib suggest a combined an...

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @AzadOncology @maughanonc 11/19 #TumorBoardTuesday #GU22
👨🏽‍🏫Mini Tweetorial 8👨🏽‍🏫
✨MAGNITUDE
1L mCRPC (HRR & non-HRR)
📍423 pts with HRR
🔹HRR gene: ATM, BRCA1, BRCA2, BRIP1, CDK12, CHEK2, FANCA, HDAC2, or PALB2
🤼Niraparib + abiraterone (212) vs PBO + abiraterone (211)
📈rPFS HR 0.76 👍🏽niraparib + AAP

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab 12/19 #TumorBoardTuesday #ProstateCancer @AttardLab @EfstathiouEleni
👨🏽‍🏫Mini Tweetorial 9👨🏽‍🏫
✨MAGNITUDE
👍🏽Effectiveness more pronounced in BRCA1/2 cohort
📈rPFS HR 0.56 👍🏽 of niraparib + abiraterone
🚫non-HRR cohort closed due to futility
📚pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/37399894/

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial - PubMed

MAGNITUDE, enrolling the largest BRCA1/2 cohort in first-line mCRPC to date, demonstrated improved r...

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @EfstathiouEleni 13/19 #TumorBoardTuesday #ProstateCancer
Based on real-world data
🧐 What proportion of mCRPC patients do NOT receive a subsequent line of therapy?

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @EfstathiouEleni 14/19 #TumorBoardTuesday
👨🏽‍🏫Mini Tweetorial 10👨🏽‍🏫
📌 Real-world data for 2L+
High attrition rates in mCRPC (~50% receiving 2L and ~21% receiving
3L or beyond)
Upfront intensification may be a better strategy than sequencing given these data
📚pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/32057714/

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States - PubMed

These real-world insights on over 2500 patients with mCRPC supplement findings from randomized contr...

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @EfstathiouEleni 15/19 #TumorBoardTuesday
Back to our case🔎
👨🏻‍Starts talazoparib + enzalutamide due to RAD51C mutation
🩸G 3 anemia
⬇️Managed with dose reduction & transfusions
🧪Good PSA response
🗓️18 mos
PSA: ⬆️ 3 ng/ml
🩻Bone scan: new spinal mets, lymph node mets, & 2 liver lesions

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @EfstathiouEleni 16/19 #TumorBoardTuesday #ProstateCancer
🔬Tumor CGP from biopsy of one of the liver lesions reveals:
RAD51C mutation
PTEN loss
TMPRSS2-ERG fusion
RB1 loss
TP53 H179Y
TMB-high (23 Muts/Mb)
🤔What would YOU do next?

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @EfstathiouEleni 17/19 #TumorBoardTuesday
👨🏽‍🏫Mini Tweetorial 11👨🏽‍🏫
✨CARD
📍Ph3
🔹previous docetaxel & ARPI
🎲Random to receive cabazitaxel OR alternate ARPI
🤼Cabaz (129) vs ARPI (126)
📈mPFS 8.0 vs 3.7mos 👍🏽cabaz (HR 0.54)
📉mOS 13.6 vs 11mos 👍🏽cabaz (HR 0.64)
📚pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/37399894/

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial - PubMed

MAGNITUDE, enrolling the largest BRCA1/2 cohort in first-line mCRPC to date, demonstrated improved r...

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @EfstathiouEleni 18/19 #TumorBoardTuesday #ProstateCancer
👨🏽‍🏫Mini Tweetorial 12👨🏽‍🏫
📌Major side effects of cabazitaxel
😴 Fatigue
🩸Cytopenia
🚽Diarrhea
🦠Infections
🦴Musculoskeletal pain
🤢Nausea/vomiting
🦵🏼💪🏾Peripheral neuropathy
📚pubmed.ncbi.nlm.nih.gov

pubmed.ncbi.nlm.nih.gov/31719685/

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort - PubMed

It was registered with the European Medicines Agency EUPASS registry, available at www.encepp.eu, as...

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @EfstathiouEleni The anemia is often fixed with dose reductions alone. Transfusions are usually not required #TumorBoardTuesday

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab @EfstathiouEleni 19/19 #TumorBoardTuesday #ProstateCancer
Back to our case🔎
🧔🏽starts on docetaxel
🧪PSA undetectable
🩻restaging scans: Rx response
🗓️9 months later
🩻scans: progression of d/s
🧔🏽Develops grade 2 neuropathy from docetaxel therapy
🧐What would you do next?

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab #PostTest Q1️⃣ #TumorBoardTuesday
👉🏽#CME Eval 🔗 integrityce.com
👉🏽ALL CME🔗 integrityce.com
🤔@neerajaiims @vinay_onc taught us choosing PARPi for #ProstateCancer, test yourself
🧐What tx?
56yo🧔🏽
🗓️2yrs on ADT
🩻new asymptomatic
PALB2-mutated CRPC
met 🦴 lesions

integrityce.com/TBT2023

Tumor Board Tuesday 2023 Conversations

Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert fac...

integrityce.com/TBTeval23

Tumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865)

Take this survey powered by surveymonkey.com. Create your own surveys for free.

@TumorBoardTues @brian_rini @HHammersMD @MattGalsky @Daniel_J_George @drenriquegrande @NazliDizman @crisbergerot @JoshMeeks @mishabeltran @morr316 @SoaresAndrey @thomashopemd @DrKarineTawagi @gulleyj1 @scserendipity1 @minaseconomides @ASanchez_UroOnc @LewisLabMSKCC @ChrisSweens1 @AminaZoubeidi @MPishvaian @JohnEbbenMDPhD @shilpaonc @neerajaiims @rafee_talukder @xiaoweimd @tompowles1 @samirzaidi @Kaochar2 @ReneeSaliby @PBarataMD @Silke_Gillessen @arkhaki @LenAppleman @DrAndreFay @AJangMD @DrYukselUrun @Tendler_S @alantanmd @drcmassard @MarkowskiGUOnc @SylvanBacaLab @DrJonesNauseef @AChakrabortyPhD @bev_chigarira @AarmstrongDuke @AttardLab #PostTest Q2️⃣ #TumorBoardTuesday
👉🏽 Free CME 🔗 integrityce.com
🧐Which HRR gene alterations obtain greater benefit from talazoparib + enzalutamide vs enzalutamide monotherapy in patients with CRPC? #ProstateCancer

integrityce.com/TBT2023

Tumor Board Tuesday 2023 Conversations

Tumor Board Tuesdays is a regularly scheduled, Twitter-based case discussion forum led by expert fac...

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | NEJM

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - PubMed

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial - PubMed

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States - PubMed

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial - PubMed

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort - PubMed

Tumor Board Tuesday 2023 Conversations

Tumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865)

Tumor Board Tuesday 2023 Conversations

Categories

More from this author

Related Threads

Popular Threads

Inherited DNA-Repair Gene Mutations in Men with Metastatic Prostate Cancer | NEJM

Prospective Comprehensive Genomic Profiling of Primary and Metastatic Prostate Tumors

Moving From Poly (ADP-Ribose) Polymerase Inhibition to Targeting DNA Repair and DNA Damage Response in Cancer Therapy

Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial - PubMed

Abiraterone and Olaparib for Metastatic Castration-Resistant Prostate Cancer

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial - PubMed

Treatment Patterns and Outcomes in Patients With Metastatic Castration-resistant Prostate Cancer in a Real-world Clinical Practice Setting in the United States - PubMed

Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial - PubMed

Overall and progression-free survival with cabazitaxel in metastatic castration-resistant prostate cancer in routine clinical practice: the FUJI cohort - PubMed

Tumor Board Tuesday 2023 Conversations

Tumor Board Tuesday Evaluation 2023 (ID: i854/i855/i862/i865)

Tumor Board Tuesday 2023 Conversations

Categories

More from this author

Related Threads

Popular Threads

Unroll Thread